Evoke Pharma Welcomes Ben Smeal to Its Board of Directors
Evoke Pharma, Inc. is excited to announce that Ben Smeal has been appointed to its Board of Directors. The company specializes in therapies for gastrointestinal (GI) diseases and aims to bring innovative treatments to patients in need. This significant appointment was made effective on a date in October 2024, following the company's recent financing activities.
Ben Smeal’s Expertise and Background
Mr. Smeal joins Evoke Pharma with a wealth of experience in investment management and corporate governance. With a career that includes notable positions at Willett Advisors, owned by Michael R. Bloomberg, and Kenmare Management, he has honed his strategic business development skills and equity investment expertise. His time at Overstock.com as Marketing Director also enriched his understanding of both traditional and digital marketing strategies.
The Importance of Corporate Governance
Mr. Smeal's extensive background has positioned him as a valuable asset in the realm of corporate governance. His past experience serving on various corporate boards enhances Evoke’s strategic direction, especially as the company continues its endeavors in the competitive pharmaceutical landscape.
Expansion of GIMOTI Access
During the announcement, Matt D'Onofrio, CEO of Evoke Pharma, expressed his enthusiasm about Mr. Smeal’s appointment. He noted that Smeal’s background in public equities and strategic insights would be crucial for expanding patient access to GIMOTI, a nasal spray treatment for diabetic gastroparesis.
Commitment to Patient Outcomes
Ben Smeal shared his thoughts on this new role, expressing that he is honored to join such a dedicated team. He resonated strongly with Evoke’s mission to improve patient outcomes in an underserved area of medicine. His passion for innovation and growth within the company promises exciting prospects for future developments.
About Evoke Pharma, Inc.
Evoke Pharma is dedicated to addressing GI disorders through the development of specialized drug therapies. Their flagship product, GIMOTI, is a unique nasal spray formulation of metoclopramide designed to relieve symptoms associated with diabetic gastroparesis in adults. This condition can severely impact quality of life, hindering the stomach’s ability to digest food efficiently, leading to various complications.
Significance of GIMOTI
Unlike oral or injectable formulations traditionally available, GIMOTI is the first FDA-approved treatment specifically for alleviating diabetic gastroparesis symptoms. As many adults worldwide suffer from this debilitating disorder, Evoke Pharma’s commitment to delivering effective treatment is paramount.
Continuing Growth and Innovation
As the pharmaceutical market evolves, Evoke Pharma remains focused on expanding its offerings and enhancing access to GIMOTI. The company is poised for future success, driven by its leadership team and innovative treatment options.
Frequently Asked Questions
Who is Ben Smeal?
Ben Smeal is the newly appointed member of the Board of Directors of Evoke Pharma, bringing extensive experience in investment management and corporate governance.
What is GIMOTI?
GIMOTI is a nasal spray formulation of metoclopramide specifically approved to treat symptoms of diabetic gastroparesis in adults.
What role does Ben Smeal have at Evoke Pharma?
Ben Smeal serves on the Board of Directors, where he contributes his expertise in public equities and strategic insights to help shape the company's direction.
What is diabetic gastroparesis?
Diabetic gastroparesis is a condition that affects the stomach's ability to empty contents normally, causing severe GI symptoms and complications.
How is Evoke Pharma addressing patient needs?
Evoke Pharma is dedicated to developing innovative treatments for GI disorders and working to expand access to its primary product, GIMOTI, for patients in need.
